250 related articles for article (PubMed ID: 36113749)
1. Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease.
Iacono D; Koga S; Peng H; Manavalan A; Daiker J; Castanedes-Casey M; Martin NB; Herdt AR; Gelb MH; Dickson DW; Lee CW
Neurobiol Dis; 2022 Nov; 174():105862. PubMed ID: 36113749
[TBL] [Abstract][Full Text] [Related]
2. Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity.
Shin D; Feltri ML; Wrabetz L
J Neurosci; 2016 Feb; 36(6):1858-70. PubMed ID: 26865610
[TBL] [Abstract][Full Text] [Related]
3. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form.
Hossain MA; Otomo T; Saito S; Ohno K; Sakuraba H; Hamada Y; Ozono K; Sakai N
Gene; 2014 Jan; 534(2):144-54. PubMed ID: 24252386
[TBL] [Abstract][Full Text] [Related]
4. Patient fibroblasts-derived induced neurons demonstrate autonomous neuronal defects in adult-onset Krabbe disease.
Lim SM; Choi BO; Oh SI; Choi WJ; Oh KW; Nahm M; Xue Y; Choi JH; Choi JY; Kim YE; Chung KW; Fu XD; Ki CS; Kim SH
Oncotarget; 2016 Nov; 7(46):74496-74509. PubMed ID: 27780934
[TBL] [Abstract][Full Text] [Related]
5. Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease.
Herdt AR; Peng H; Dickson DW; Golde TE; Eckman EA; Lee CW
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628569
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy.
Matthes F; Andersson C; Stein A; Eistrup C; Fogh J; Gieselmann V; Wenger DA; Matzner U
Exp Neurol; 2015 Sep; 271():36-45. PubMed ID: 25956830
[TBL] [Abstract][Full Text] [Related]
7. Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.
Potter GB; Santos M; Davisson MT; Rowitch DH; Marks DL; Bongarzone ER; Petryniak MA
Hum Mol Genet; 2013 Sep; 22(17):3397-414. PubMed ID: 23620143
[TBL] [Abstract][Full Text] [Related]
8. Genetic ablation of Saposin-D in Krabbe disease eliminates psychosine accumulation but does not significantly improve demyelination.
Watanabe T; Tsuboi K; Matsuda N; Ishizuka Y; Go S; Watanabe E; Ono A; Okamoto Y; Matsuda J
J Neurochem; 2023 Aug; 166(4):720-746. PubMed ID: 37337846
[TBL] [Abstract][Full Text] [Related]
9. Late onset Krabbe disease due to the new GALC p.Ala543Pro mutation, with intriguingly high residual GALC activity in vitro.
Krägeloh-Mann I; Harzer K; Rostásy K; Beck-Wödl S; Bornemann A; Böhringer J; Bevot A; Beck V; Merkel G; Pechan M
Eur J Paediatr Neurol; 2017 May; 21(3):522-529. PubMed ID: 28109651
[TBL] [Abstract][Full Text] [Related]
10. A new compound heterozygous mutation in adult-onset Krabbe disease.
Meng X; Li Y; Lian Y; Li Y; Du L; Xie N; Wang C
Int J Neurosci; 2020 Dec; 130(12):1267-1271. PubMed ID: 32064984
[No Abstract] [Full Text] [Related]
11. Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease.
Ribbens JJ; Moser AB; Hubbard WC; Bongarzone ER; Maegawa GH
Mol Genet Metab; 2014 Feb; 111(2):172-83. PubMed ID: 24094551
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy.
Hawkins-Salsbury JA; Shea L; Jiang X; Hunter DA; Guzman AM; Reddy AS; Qin EY; Li Y; Gray SJ; Ory DS; Sands MS
J Neurosci; 2015 Apr; 35(16):6495-505. PubMed ID: 25904800
[TBL] [Abstract][Full Text] [Related]
13. Residual galactosylsphingosine (psychosine) beta-galactosidase activities and associated GALC mutations in late and very late onset Krabbe disease.
Harzer K; Knoblich R; Rolfs A; Bauer P; Eggers J
Clin Chim Acta; 2002 Mar; 317(1-2):77-84. PubMed ID: 11814461
[TBL] [Abstract][Full Text] [Related]
14. Developmental defects and aberrant accumulation of endogenous psychosine in oligodendrocytes in a murine model of Krabbe disease.
Inamura N; Kito M; Go S; Kishi S; Hosokawa M; Asai K; Takakura N; Takebayashi H; Matsuda J; Enokido Y
Neurobiol Dis; 2018 Dec; 120():51-62. PubMed ID: 30176352
[TBL] [Abstract][Full Text] [Related]
15. Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of Krabbe disease.
Weinstock NI; Kreher C; Favret J; Nguyen D; Bongarzone ER; Wrabetz L; Feltri ML; Shin D
Nat Commun; 2020 Oct; 11(1):5356. PubMed ID: 33097716
[TBL] [Abstract][Full Text] [Related]
16. Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease.
Heller GJ; Marshall MS; Issa Y; Marshall JN; Nguyen D; Rue E; Pathmasiri KC; Domowicz MS; van Breemen RB; Tai LM; Cologna SM; Crocker SJ; Givogri MI; Sands MS; Bongarzone ER
Mol Ther; 2021 May; 29(5):1883-1902. PubMed ID: 33508430
[TBL] [Abstract][Full Text] [Related]
17. Insights into the Pathogenesis and Treatment of Krabbe Disease.
Bongarzone ER; Escolar ML; Gray SJ; Kafri T; Vite CH; Sands MS
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():689-96. PubMed ID: 27491217
[TBL] [Abstract][Full Text] [Related]
18. GALC mutations in Chinese patients with late-onset Krabbe disease: a case report.
Zhuang S; Kong L; Li C; Chen L; Zhang T
BMC Neurol; 2019 Jun; 19(1):122. PubMed ID: 31185936
[TBL] [Abstract][Full Text] [Related]
19. Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration.
Kreher C; Favret J; Weinstock NI; Maulik M; Hong X; Gelb MH; Wrabetz L; Feltri ML; Shin D
PLoS Biol; 2022 Jul; 20(7):e3001661. PubMed ID: 35789331
[TBL] [Abstract][Full Text] [Related]
20. Reduction in miR-219 expression underlies cellular pathogenesis of oligodendrocytes in a mouse model of Krabbe disease.
Inamura N; Go S; Watanabe T; Takase H; Takakura N; Nakayama A; Takebayashi H; Matsuda J; Enokido Y
Brain Pathol; 2021 Sep; 31(5):e12951. PubMed ID: 33822434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
